GW Pharmaceuticals Debt 2024

GW Pharmaceuticals Aktienanalyse

What does GW Pharmaceuticals do?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding GW Pharmaceuticals's Debt Structure

GW Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing GW Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to GW Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in GW Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about GW Pharmaceuticals stock

What is the debt of GW Pharmaceuticals this year?

GW Pharmaceuticals has a debt level of 0 USD this year.

What was the debt of GW Pharmaceuticals compared to the previous year?

The debt of GW Pharmaceuticals has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in GW Pharmaceuticals?

High debt can pose a risk for investors of GW Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of GW Pharmaceuticals?

Low debt means that GW Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from GW Pharmaceuticals affect the company?

An increase in debt of GW Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of GW Pharmaceuticals affect the company?

A reduction in debt of GW Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of GW Pharmaceuticals?

Some factors that can influence the debt of GW Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of GW Pharmaceuticals so important for investors?

The debts of GW Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can GW Pharmaceuticals take to change the debt?

To change the debt, GW Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does GW Pharmaceuticals pay?

Over the past 12 months, GW Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GW Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of GW Pharmaceuticals?

The current dividend yield of GW Pharmaceuticals is .

When does GW Pharmaceuticals pay dividends?

GW Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GW Pharmaceuticals?

GW Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of GW Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GW Pharmaceuticals located?

GW Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GW Pharmaceuticals from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did GW Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of GW Pharmaceuticals in the year 2023?

In the year 2023, GW Pharmaceuticals distributed 0 USD as dividends.

In which currency does GW Pharmaceuticals pay out the dividend?

The dividends of GW Pharmaceuticals are distributed in USD.